Home > Insider Trading > Filing (0001410939-22-000023)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1410939	Iveric Bio Inc.	ISEE	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1277478	Glenn Sblendorio	C/O Iveric Bio, Inc. 8 Sylvan Way Parsippany NJ 07054	Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2022-03-18	3,479	$2.94	283,168	No	4	M	Direct
Common Stock	Disposition	2022-03-18	3,479	$17.00	279,689	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2022-03-18	3,479	$0.00	3,479	$2.94

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
387,144		2027-12-18	No	4	M	Direct

Footnotes

The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2021, as previously disclosed in the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, as filed with the Securities and Exchange Commission on November 9, 2021.
This total includes 556 shares acquired by the Reporting Person on March 15, 2022, under the Registrant's 2016 Employee Stock Purchase Plan that were not previously reported.
The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker in multiple transactions effected at prices ranging from $17.00 to $17.01 per share on March 18, 2022. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Registrant or a security holder of the Registrant, information regarding the number of shares sold at each price within the range.
This stock option award was granted on December 19, 2017 and vests with respect to 25% of the shares subject to the option on the first anniversary of the grant date and with respect to the remaining shares in approximately equal monthly installments through the fourth anniversary of the grant date.